These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 4082082

  • 1. Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
    Simpson IA, Lorimer AR, Walker ID, Davidson JF.
    Thromb Haemost; 1985 Aug 30; 54(2):442-4. PubMed ID: 4082082
    [Abstract] [Full Text] [Related]

  • 2. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
    Fonseca FA, Novazzi JP, Cendoroglo MS, Duarte M, Almeida Pinto LE, Rabelo LM, da Rocha Martinez TL.
    Arq Bras Cardiol; 1996 Jan 30; 66(1):33-5. PubMed ID: 8731322
    [Abstract] [Full Text] [Related]

  • 3. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B, Gasparini Casari M, DiBlasio P, Zirilli E.
    Arzneimittelforschung; 1981 Jan 30; 31(10a):1863-6. PubMed ID: 7032534
    [Abstract] [Full Text] [Related]

  • 4. [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
    Honorato Pérez J, Azanza Perea JR.
    Rev Med Univ Navarra; 1982 Mar 30; 26(1):51-4. PubMed ID: 7111953
    [Abstract] [Full Text] [Related]

  • 5. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A, McAuliff MP, Beyler AL.
    J Pharm Sci; 1979 Dec 30; 68(12):1557-8. PubMed ID: 529054
    [Abstract] [Full Text] [Related]

  • 6. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
    de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C.
    Thromb Haemost; 1997 Jan 30; 77(1):75-9. PubMed ID: 9031453
    [Abstract] [Full Text] [Related]

  • 7. [A clofibric acid derivative with hypolipemic and platelet antiaggregant action].
    Dănilă G, Nechifor M, Filip M, Păduraru I, Ifrim C, Grădinariu D, Papa V, Manolescu A, Bădescu A.
    Rev Med Chir Soc Med Nat Iasi; 1988 Jan 30; 92(1):127-32. PubMed ID: 3393745
    [No Abstract] [Full Text] [Related]

  • 8. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA, Bracons R, Vicens B, Zapatero J, Bruseghini L.
    Arzneimittelforschung; 1981 Jan 30; 31(10a):1852-5. PubMed ID: 7198465
    [Abstract] [Full Text] [Related]

  • 9. Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia.
    Angelin B, Einarsson K, Leijd B.
    Eur J Clin Invest; 1984 Feb 30; 14(1):73-8. PubMed ID: 6421601
    [Abstract] [Full Text] [Related]

  • 10. Experimental pharmacological study of moroxybrate, a hypolipidaemic, antithrombotic, antiatheromatous agent.
    Moreau P, Jacotot B, Tillement JP.
    J Pharm Pharmacol; 1987 Jan 30; 39(1):35-8. PubMed ID: 2880981
    [Abstract] [Full Text] [Related]

  • 11. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct 30; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 12. Plafibride tolerance trial in healthy volunteers.
    Dalmau J, Vicens B, Zapatero J, Bruseghini L.
    Arzneimittelforschung; 1981 Oct 30; 31(10a):1845-9. PubMed ID: 7198463
    [Abstract] [Full Text] [Related]

  • 13. Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats.
    Herbert JM, Bernat A, Chatenet-Duchène L.
    Blood Coagul Fibrinolysis; 1999 Jul 30; 10(5):239-44. PubMed ID: 10456614
    [Abstract] [Full Text] [Related]

  • 14. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M, Mongiellová V, Huttová D, Cibulová L, Krivosíková Z, Spustová V, Dzúrik R.
    J Cardiovasc Pharmacol; 2001 Nov 30; 38(5):651-6. PubMed ID: 11602811
    [Abstract] [Full Text] [Related]

  • 15. [Effectiveness of ciprofibrate. Open study in a Portuguese population].
    Silva JM, Branco MC, Pereira M, Figueiredo H, Jesus LC, de Moura JP, Ferreira MR, Serra e Silva P.
    Rev Port Cardiol; 1995 Apr 30; 14(4):313-22, 284. PubMed ID: 7612280
    [Abstract] [Full Text] [Related]

  • 16. The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E.
    Fu T, Kashireddy P, Borensztajn J.
    Biochem J; 2003 Aug 01; 373(Pt 3):941-7. PubMed ID: 12713444
    [Abstract] [Full Text] [Related]

  • 17. Bezafibrate treatment in primary hypercholesterolaemia. Possibility of intermittent treatment.
    Fringes B, Riede UN, von Deimling O.
    Atherosclerosis; 1982 Sep 01; 44(3):391-2. PubMed ID: 7150401
    [No Abstract] [Full Text] [Related]

  • 18. Bioavailability of plafibride in healthy volunteers.
    Santaniello E, Conti F, Vilageliu J, Bruseghini L.
    Arzneimittelforschung; 1981 Sep 01; 31(10a):1850-2. PubMed ID: 7198464
    [Abstract] [Full Text] [Related]

  • 19. [Effect of Complamin on fibrinolysis and platelet aggregation in the aged].
    Matijević N, Sisić I, Korolija P, Pendić B.
    Bilt Hematol Transfuz; 1980 Sep 01; 8(1):37-43. PubMed ID: 7337681
    [Abstract] [Full Text] [Related]

  • 20. Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers.
    Feller DR, Kamanna VS, Newman HA, Romstedt KJ, Witiak DT, Bettoni G, Bryant SH, Conte-Camerino D, Loiodice F, Tortorella V.
    J Med Chem; 1987 Aug 01; 30(8):1265-7. PubMed ID: 2441050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.